TY - JOUR T1 - Interstitial lung disease associated by gemcitabine chemotherapy in non-small lung cancer patients: Analysis based on the data in practical use with confirmed denominator JF - European Respiratory Journal JO - Eur Respir J VL - 38 IS - Suppl 55 SP - p3741 AU - Yukiko Miura AU - Yoshinobu Saito AU - Yuji Minegishi AU - Arata Azuma AU - Akihiko Gemma Y1 - 2011/09/01 UR - http://erj.ersjournals.com/content/38/Suppl_55/p3741.abstract N2 - Background: Gemcitabine (GEM), which is often used for non-small cell lung cancer (NSCLC), was reported to induce interstitial lung disease (ILD) in Japan. Presently, all-case postmarketing surveillance came to be generally conducted after the launch of new anti-cancer drug to investigate less-frequently but serious adverse drug reactions such as ILD in Japan. However, all-case surveillance had not been conducted for GEM and there is few data of GEM-induced ILD incidence in NSCLC practical use with confirmed denominator.Objectives: To investigate incidence rate, severity and risk factors of ILD in NSCLC patients with GEM chemotherapy in single institute.Methods: We conducted a retrospective observational study of all NSCLC patients who received GEM in our hospital through medical records.Results: 172 patients received chemotherapy for NSCLC with GEM. ILD developed in five (2.9%) among these patients. ILD developed 10 to 80 days after the first administration of GEM. Of the five patients, four patients improved by steroid, whereas one patient died despite steroid therapy. Patient's characteristics reported to be as risk factors of drug-induced ILD, such as age, performance status, and smoking history, concomitant use of anti-cancer drugs, were compared between ILD and non-ILD patients. However, significant differences were not detected.Conclusions: Incidence rate of GEM-associated ILD in NSCLC patients was 2.9% in this study. Most of the patients who developed ILD had a good prognosis but one of them had a fatal outcome. We weigh the difference between our result and previous reports of GEM-associated ILD. ER -